Detalles de la búsqueda
1.
Pregnancy After Breast Cancer in Young BRCA Carriers: An International Hospital-Based Cohort Study.
JAMA
; 331(1): 49-59, 2024 01 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38059899
2.
70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age.
Lancet Oncol
; 22(4): 476-488, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33721561
3.
Tolerability and toxicity of trastuzumab or trastuzumab + lapatinib in older patients: a sub-analysis of the ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D).
Breast Cancer Res Treat
; 185(1): 107-116, 2021 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-32951084
4.
Body Mass Index and Weight Change in Patients With HER2-Positive Early Breast Cancer: Exploratory Analysis of the ALTTO BIG 2-06 Trial.
J Natl Compr Canc Netw
; 19(2): 181-189, 2021 01 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33401235
5.
Clustering of known low and moderate risk alleles rather than a novel recessive high-risk gene in non-BRCA1/2 sib trios affected with breast cancer.
Int J Cancer
; 147(10): 2708-2716, 2020 11 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-32383162
6.
Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and/or trastuzumab Treatment Optimization Trial.
Br J Cancer
; 122(10): 1453-1460, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32203207
7.
Addition of a 161-SNP polygenic risk score to family history-based risk prediction: impact on clinical management in non-BRCA1/2 breast cancer families.
J Med Genet
; 56(9): 581-589, 2019 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-31186341
8.
Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy.
Int J Mol Sci
; 21(4)2020 Feb 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-32085669
9.
Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2-positive early breast cancer: Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials.
Cancer
; 125(2): 307-316, 2019 01 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-30335191
10.
Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTTO (BIG 2-06) randomized clinical trial.
Breast Cancer Res Treat
; 177(1): 103-114, 2019 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-31134488
11.
Correction to: Tolerability and toxicity of trastuzumab or trastuzumab + lapatinib in older patients: a subanalysis of the ALTTO trial (BIG 206; NCCTG (Alliance) N063D).
Breast Cancer Res Treat
; 191(1): 225, 2022 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-34625860
12.
Functional Analysis of Missense Variants in the Putative Breast Cancer Susceptibility Gene XRCC2.
Hum Mutat
; 37(9): 914-25, 2016 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-27233470
13.
COMPLEXO: identifying the missing heritability of breast cancer via next generation collaboration.
Breast Cancer Res
; 15(3): 402, 2013 Jun 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-23809231
14.
Rare variants in XRCC2 as breast cancer susceptibility alleles.
J Med Genet
; 49(10): 618-20, 2012 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-23054243
15.
High-dose alkylating chemotherapy in BRCA-altered triple-negative breast cancer: the randomized phase III NeoTN trial.
NPJ Breast Cancer
; 9(1): 75, 2023 Sep 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37689749
16.
Tumor Cellularity and Infiltrating Lymphocytes as a Survival Surrogate in HER2-Positive Breast Cancer.
J Natl Cancer Inst
; 114(3): 467-470, 2022 03 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-33787900
17.
Ten-year follow-up of the observational RASTER study, prospective evaluation of the 70-gene signature in ER-positive, HER2-negative, node-negative, early breast cancer.
Eur J Cancer
; 175: 169-179, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-36126477
18.
Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials.
NPJ Breast Cancer
; 8(1): 68, 2022 May 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-35610260
19.
Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant.
Eur J Cancer
; 164: 39-51, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-35172272
20.
Evaluation of multiple transcriptomic gene risk signatures in male breast cancer.
NPJ Breast Cancer
; 7(1): 98, 2021 Jul 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-34312396